scout

All News

Do you know what percentage of lung cancer patients present with intracranial metastases? Or the most common renal abnormality seen in the presence of lung cancer? Answer these questions and more.

Analyses from the phase III ALSYMPCA trial showed that treatment with radium-223 resulted in quality-of-life improvements over placebo in patients with castration-resistant prostate cancer and symptomatic bone metastases.

The FDA has approved the first single-dose intravenous NK1 receptor antagonist, fosaprepitant dimeglumine (Emend), for the treatment of nausea and vomiting that can accompany the use of moderately and highly emetogenic chemotherapy.